25 Antibody-Cytokine hu14.18-IL2 Retains Antibody and IL-2 Activity Following Clinical Administration and Induces IL-2- Mediated Immune Activation
Hank JA¹, Albertini MR¹, Gan J¹, Surfus J¹, King D¹, Schalch H¹, Kim K¹, Dahl T4, Kashala O4, Sturmhoefel K4, Reisfeld RA², Gillies SD³, Sondel PM¹
¹The; University of Wisconsin Comprehensive Cancer Center-Madison WI; ²The; Scripps Research Institute-La Jolla CA; ³Lexigen; Pharmaceuticals-Lexington MA; and 4EMD Pharmaceuticals-Durham NC
26 Vaccination of prostate cancer patients with prostate specific antigen and biological adjuvants reduces serum PSA
Head JF, Jiang XP, Elliott RL
Mastology Research Institute of the Elliott Hailey Head Breast Cancer Research and Treatment Center, Baton Rouge, LA
28 Sequential Photon or Neutron Radiation and Interleukin-2 for Prostate Carcinoma Bone Tumors in an Experimental Model
Hillman GG, Maughan RL, Grignon DJ, Che M, Yudelev M, Wang Y, Layer A, Wright JL, and Forman JD.
Departments of Radiation Oncology and Pathology, Karmanos Cancer Institute at Wayne State University. Detroit, MI
29 Administration of either anit-CD40 or interleukin-12 following lethal total body irradiation induces an acute lethal toxicity affecting the gut
Hixon JA¹, Wigginton JM², Wiltrout RH³, Blazar BR4, Anver MR5, Murphy WJ1¹Intramural; Research Support Program, Science Applications International Corporation (SAIC)-Frederick, Maryland; ²Investigational; Biologics Group, National Cancer Institute-Frederick, MD; ³Laboratory; of Experimental Immuology, National Cancer Institute-Frederick, MD; 4Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN; 5Pathology Histotechnology Laboratory, SAIC-Frederick, MD
30 Molecular Mechanism for IL-2 Plus IL-12 Regulation of Interferon-Gamma mRNA in Human NK cells
Hodge, Deborah L.¹, Martinez, Alfredo³, Julias, John G.², Taylor, Lynn S.¹ and Young, Howard A.¹
¹Laboratory; of Experimental Immunology, ²HIV; Drug Resistance Program, NCI-CCR at Frederick, Frederick, MD; ³Dept.; Cell and Cancer Biology, NCI, Bethesda, MD
31 Non-Myeloablative Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: the University of Chicago Experience
Hu HS¹, Rini BI², Zimmerman TM¹, Gajewski TF¹, Stadler WM¹, Vogelzang NJ1
¹University; of Chicago, Chicago, IL; ²University; of California at San Francisco, San Francisco, CA
32 Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen
Chien-Fu Hung, Wen-Fang Cheng, Liangmei He, Morris Ling, and T.-C. Wu
Pathology, Johns Hopkins University Baltimore, MD
33 Anti-tumour effect of recombinant mycobacteria genetically engineered to secrete interleukin-15 and tumour necrosis factor
Young, S¹, Murphy, M¹, Xhu, X¹, O’Donnell, MA², Selby, P¹, James, K³, Jackson AM1
¹Applied; Immunology Group, Imperial Cancer Research Fund, Leeds, United Kingdom; ²Dept; Urology, Iowa University, IA; ³Dept; Surgery, University of Edinburgh, United Kingdom
34 T9 Glioma Cells Expressing Membrane Macrophage Colony Stimulating Factor (mM-CSF) Produce CD4+ Mediated Protective Immunity Against T9 Intracranial Gliomas and Systemic Immunity Against Different Syngeneic Gliomas
Jadus MR, Sanchez R, Williams CC, Daza JL, Dan Q, Xu Q, Chen Y, Delgado C, Arpajirakul N, Jeffes EWB, Kim RC, Wepsic HT
Diagnostic & Molecular Health Care Group, Veterans Affairs Medical Center, Long Beach, CA and Pathology Department, University of California, Irvine, CA